FDAnews
www.fdanews.com/articles/185674-edwards-lifesciences-earns-ce-mark-for-centera-valve

Edwards Lifesciences Earns CE Mark for CENTERA Valve

February 16, 2018

Edwards Lifesciences received a CE Mark for its self-expanding CENTERA valve for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery.

The valve is repositionable and retrievable and can be delivered through a motorized delivery system.

The CE Mark was based on the trial results from a study of 203 high-risk patients at 23 centers in Europe, Australia and New Zealand.

View today's stories